Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Parallel Group Study For Assessing The Efficacy And Safety Of Renvela® Tablets For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease Not On Dialysis Versus Placebo

NCT03001011 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03001011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03001011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Parallel Group Study For Assessing The Efficacy And Safety Of Renvela® Tablets For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease Not On Dialysis Versus Placebo
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
June 7, 2017
Completion date
August 16, 2019
Enrollment
202 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

hyperphosphatemia